Home 2015

Archives

medication errors

Preventing medication errors by empowering patients

Preventable medication errors cost the U.S. healthcare system more than $21 billion annually, according to the National Priorities Partnership and National Quality Forum. This...
drug-seeking

Doctor shopping and prescription substance use disorders: A nursing response

Prescription substance use disorders (SUDs) have a serious impact on society. In 2013, 6.5 million adults admitted to illicit use of prescription medications. The...
medication errors

Preventing high-alert medication errors in hospital patients

Mistakes involving medications are among the most common healthcare errors. Medication errors lengthen hospital stays, increase inpatient expenses, and lead to more than 7,000...
Excessive opioids

Excessive opioids lead to a close call for a burn patient

Tim Waters, age 28, is admitted to a burn intensive care unit for treatment after a natural gas explosion in his home causes deep...

Improving posthospital medication management for chronically ill older adults

For chronically ill older adults who take multiple medications, a hospital stay can result in various medication-related changes. Nurses administer their medications to them. Their medication...

What’s new in anticoagulation for patients with atrial fibrillation?

Mrs. Muriel H, age 78, is admitted to the medical-surgical unit with GI bleeding. She has a 5-year history of atrial fibrillation and has...

FDA approves Afrezza

On June 27, the U.S. Food and Drug Administration (FDA) approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control...

FDA approves drug for treating rare type of non-Hodgkin lymphoma

On July 3, the U.S. Food and Drug Administration (FDA) approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma, a rare...

FDA approves new product to treat hereditary angioedema

On July 16, the U.S. Food and Drug Administration (FDA) approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks...

Study: Higher Hgb or receiving EPO doesn’t improve neuro outcomes in patients with TBI

In patients with a traumatic brain injury (TBI), the administration of the hormone erythropoietin (EPO) or maintaining a higher hemoglobin (Hgb) concentration through blood...

FDA approves new drug for serious skin infections

On June 20, the U.S. Food and Drug Administration (FDA) approved Sivextro (tedizolid phosphate) to treat patients with acute bacterial skin and skin structure...

Study: Thrombolytics significantly reduce mortality in sudden-onset PE

According to a study in JAMA, adding thrombolytics to conventional approaches when treating patients with sudden-onset pulmonary embolism is associated with 47% fewer deaths...

FDA approves Zykadia for NSCLC

On April 29, the U.S. Food and Drug Administration (FDA) approved Zykadia for patients with a certain type of late-stage non-small cell lung cancer...